Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcia Hall

Showing results (31-40 of 71) with videos related to

Pageof 8
Sort By:
Oncotarget|May 17, 2018
Prognostic value of the DNA integrity index in patients with malignant lung tumorsDimple Y Chudasama, Zeynep Aladag, Mayla I Felicien, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 24, 2020
Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitorsRosemary Lord, Jyoti Rauniyar, Tamsin Morris, et al.
Journal of Clinical Medicine|September 5, 2020
H2A Histone Family Member X (H2AX) Is Upregulated in Ovarian Cancer and Demonstrates Utility as a Prognostic Biomarker in Terms of Overall SurvivalSayeh Saravi, Eriko Katsuta, Jeyarooban Jeyaneethi, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 30, 2019
Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR studyMarcia Hall, Gianfilippo Bertelli, Louise Li, et al.
Carcinogenesis|November 11, 2017
Identification of cancer biomarkers of prognostic value using specific gene regulatory networks (GRN): a novel role of RAD51AP1 for ovarian and lung cancersDimple Chudasama, Valeria Bo, Marcia Hall, et al.
BMC Cancer|December 21, 2014
A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocolShibani Nicum, Corran Roberts, Lucy Boyle, et al.
Frontiers in Oncology|July 25, 2019
Surfactant Protein D as a Potential Biomarker and Therapeutic Target in Ovarian CancerJuhi Kumar, Valamarthy Murugaiah, Georgios Sotiriadis, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 13, 2023
AN0025, a novel antagonist of PGE2-receptor E-type 4 (EP4), in combination with total neoadjuvant treatment of advanced rectal cancerLucjan Wyrwicz, Mark Saunders, Marcia Hall, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|July 5, 2020
British Gynaecological Cancer Society (BGCS) vulval cancer guidelines: Recommendations for practiceJo Morrison, Peter Baldwin, Lynn Buckley, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 25, 2017
Surgery for Recurrent Uterine Cancer: Surgical Outcomes and Implications for Survival-A Case SeriesLavinia Domenici, Katherine Nixon, Flavia Sorbi, et al.
Pageof 8

Showing results (31-40 of 71) with videos related to

Sort By:
Pageof 8
Oncotarget|May 17, 2018
Prognostic value of the DNA integrity index in patients with malignant lung tumorsDimple Y Chudasama, Zeynep Aladag, Mayla I Felicien, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 24, 2020
Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitorsRosemary Lord, Jyoti Rauniyar, Tamsin Morris, et al.
Journal of Clinical Medicine|September 5, 2020
H2A Histone Family Member X (H2AX) Is Upregulated in Ovarian Cancer and Demonstrates Utility as a Prognostic Biomarker in Terms of Overall SurvivalSayeh Saravi, Eriko Katsuta, Jeyarooban Jeyaneethi, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 30, 2019
Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR studyMarcia Hall, Gianfilippo Bertelli, Louise Li, et al.
Carcinogenesis|November 11, 2017
Identification of cancer biomarkers of prognostic value using specific gene regulatory networks (GRN): a novel role of RAD51AP1 for ovarian and lung cancersDimple Chudasama, Valeria Bo, Marcia Hall, et al.
BMC Cancer|December 21, 2014
A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocolShibani Nicum, Corran Roberts, Lucy Boyle, et al.
Frontiers in Oncology|July 25, 2019
Surfactant Protein D as a Potential Biomarker and Therapeutic Target in Ovarian CancerJuhi Kumar, Valamarthy Murugaiah, Georgios Sotiriadis, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 13, 2023
AN0025, a novel antagonist of PGE2-receptor E-type 4 (EP4), in combination with total neoadjuvant treatment of advanced rectal cancerLucjan Wyrwicz, Mark Saunders, Marcia Hall, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|July 5, 2020
British Gynaecological Cancer Society (BGCS) vulval cancer guidelines: Recommendations for practiceJo Morrison, Peter Baldwin, Lynn Buckley, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 25, 2017
Surgery for Recurrent Uterine Cancer: Surgical Outcomes and Implications for Survival-A Case SeriesLavinia Domenici, Katherine Nixon, Flavia Sorbi, et al.
Pageof 8